Emily Dimango, MD
Pulmonary Disease · New York, NYNPI 1407933195
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Gilead at 44.5% of the total. Reporting peaked in 2019 at $31,000 and has fallen 99.6% since, to $134 in 2025. Among pulmonary disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 112 payments — averaging $524.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$26K
- AstraZeneca$20K
- Mylan Specialty L.p.$5K
- Boehringer Ingelheim$3K
- PARI Respiratory Equipment, Inc.$2K
- Boehringer Ingelheim International GmbH$1K
- plus $2K from 10 others
Across 37 payments — averaging $34,945 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$1.2M
- Insmed, Inc.$25K
- Novartis$22K
- Boehringer Ingelheim$16K
What the payments were for
- Consulting fees$20,13534%
- Speaking & faculty fees$29,90251%
- Travel & lodging$6,38411%
- Food & beverage$2,3014%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 36 | $26,129 |
| AstraZeneca | 34 | $20,021 |
| Mylan Specialty L.p. | 10 | $4,982 |
| Boehringer Ingelheim | 3 | $2,654 |
| PARI Respiratory Equipment, Inc. | 2 | $1,628 |
| Boehringer Ingelheim International GmbH | 4 | $1,446 |
| Vertex | 1 | $1,380 |
| Baxter Healthcare | 6 | $162 |
| GSK | 7 | $150 |
| Chiesi USA, Inc. | 2 | $43 |
| AbbVie(2 entities) | 2 | $41 |
| Philips North America LLC | 1 | $28 |
| Regeneron Healthcare Solutions, Inc. | 1 | $26 |
| Insmed, Inc. | 1 | $17 |
| Sanofi | 1 | $13 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AIRSUPRA$6,099
- Cayston$5,470
- TOBI$4,726
- FASENRA$4,565
- KITABIS PAK$1,628
How this compares
$58,734 in reported general payments places this provider in the 95th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 129 | $3,454,697 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 268 | $180,038 |
| TezspireTezepelumab-Ekko | 39 | $168,623 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 13 | $115,399 |
| Fasenra PenBenralizumab | 16 | $92,536 |
| Breo ElliptaFluticasone/Vilanterol | 161 | $73,505 |
| Dupixent PenDupilumab | 11 | $65,011 |
| PertzyeLipase/Protease/Amylase | 17 | $63,882 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $10,867 |
| DuleraMometasone/Formoterol | 25 | $9,438 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 305 | $9,106 |
| Spiriva RespimatTiotropium Bromide | 14 | $6,878 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $5,923 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 29 | $5,360 |
| Advair DiskusFluticasone Propion/Salmeterol | 21 | $4,339 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| VertexTrikafta | $1,380 | $3,454,697129 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $150 | $259,467442 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $20,021 | $183,13073 claims |
| MerckDulera | $13 | $9,43825 claims |
| Boehringer IngelheimSpiriva Respimat | $2,654 | $6,87814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in New York
- Charles PowellNew York$654K
- Bisher AkilNew York$480K
- Sonali SethiNew York$388K
- Johnathan RaskinNew York$338K
- Monica KraftNew York$247K
- Jamie BessichNew York$226K
- Ronald CrystalNew York$213K
- Michael NiedermanNew York$176K
- Wilfredo TalaveraNew York$145K
- Josanna Rodriguez-LopezNew York$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.